EVOTF (Evotec SE) Cyclically Adjusted Revenue per Share: $4.70 (As of Mar. 2026)


EVOTF Evotec SE EVOTF
65 GF Score
Price $6.69
GF Value $10.31
! 5 Warning Signs
View Full Analysis

What is Evotec SE Cyclically Adjusted Revenue per Share?

Evotec SE EVOTF 65 Cyclically Adjusted Revenue per Share is $4.70 as of Mar. 2026. GuruFocus rates EVOTF with a GF Score™ of 65/100 and a GF Value™ of $10.31. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Evotec SE's adjusted revenue per share for the three months ended in Mar. 2026 was $1.020. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.70 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Evotec SE's average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 18.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Evotec SE was 23.00% per year. The lowest was 14.90% per year. And the median was 22.40% per year.

As of today (2026-07-12), Evotec SE's current stock price is $6.69. Evotec SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $4.70. Evotec SE's Cyclically Adjusted PS Ratio of today is 1.42.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Evotec SE was 25.76. The lowest was 1.11. And the median was 14.58.


Evotec SE  (OTCPK:EVOTF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Evotec SE's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.69/4.70
=1.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Evotec SE was 25.76. The lowest was 1.11. And the median was 14.58.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Evotec SE Cyclically Adjusted Revenue per Share Related Terms


Evotec SE Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Evotec SE's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Cyclically Adjusted Revenue per Share Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.23 2.70 3.38 3.78 5.51

Evotec SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.74 4.08 4.28 5.51 4.70

EVOTF vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evotec SE's Cyclically Adjusted PS Ratio falls into.


EVOTF
65GF Score
Evotec SE EVOTF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evotec SE's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.02/131.2583*131.2583
=1.020

Current CPI (Mar. 2026) = 131.2583.

Evotec SE Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.322 100.717 0.420
201609 0.382 101.017 0.496
201612 0.349 101.217 0.453
201703 0.390 101.417 0.505
201706 0.410 102.117 0.527
201709 0.550 102.717 0.703
201712 0.741 102.617 0.948
201803 0.683 102.917 0.871
201806 0.771 104.017 0.973
201809 0.786 104.718 0.985
201812 0.748 104.217 0.942
201903 0.787 104.217 0.991
201906 0.780 105.718 0.968
201909 0.840 106.018 1.040
201912 0.924 105.818 1.146
202003 0.874 105.718 1.085
202006 0.832 106.618 1.024
202009 1.009 105.818 1.252
202012 1.056 105.518 1.314
202103 0.966 107.518 1.179
202106 1.013 108.486 1.226
202109 1.142 109.435 1.370
202112 1.224 110.384 1.455
202203 1.026 113.968 1.182
202206 1.030 115.760 1.168
202209 0.974 118.818 1.076
202212 1.444 119.345 1.588
202303 1.292 122.402 1.385
202306 1.043 123.140 1.112
202309 1.184 124.195 1.251
202312 1.239 123.773 1.314
202403 1.280 125.038 1.344
202406 1.106 125.882 1.153
202409 1.157 126.198 1.203
202412 1.306 127.041 1.349
202503 1.218 127.779 1.251
202506 1.112 128.412 1.137
202509 1.083 129.255 1.100
202512 1.671 129.361 1.696
202603 1.020 131.258 1.020

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $4.70 mean?
Evotec SE (EVOTF) has a Cyclically Adjusted Revenue per Share of $4.70 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Evotec SE and its competitors.
Is Evotec SE's Cyclically Adjusted Revenue per Share too high?
Evotec SE's current Cyclically Adjusted Revenue per Share is $4.70. Overall, Evotec SE has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Evotec SE's Cyclically Adjusted Revenue per Share of $4.70 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Evotec SE and its competitors. Evotec SE's current Cyclically Adjusted Revenue per Share is $4.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Evotec SE (EVOTF) has a current Cyclically Adjusted Revenue per Share of $4.70. The stock's GF Value™ is $10.31, compared to a current price of $6.69 — trading 35.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $4.70. Evotec SE's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Evotec SE (EVOTF), the current Cyclically Adjusted Revenue per Share is $4.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (EVOTF) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of $6.69 is trading 35.1% below its estimated GF Value™ of $10.31.

Key valuation signals for EVOTF:

  • Cyclically Adjusted Revenue per Share: $4.70
  • GF Value™: $10.31 vs. price of $6.69 (35.1% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the EVOTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
65GF Score

Get the complete analysis for EVOTF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.69
Price
$10.31
GF Value